Cantor Fitzgerald raised the firm’s price target on Exagen (XGN) to $10 from $7 and keeps an Overweight rating on the shares. The company reported strong Q2 operating results and raised the top-end of FY25 revenue guidance, the analyst tells investors in a research note. Cantor remains excited about Exagen as the company continues to roll out new biomarkers that stand to improve sensitivity, which should result in incremental adoption in addition to being accretive to average selling price.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
- Exagen price target raised to $11 from $8 at Canaccord
- Exagen’s Strong Q2 Performance and Growth Strategy Justify Buy Rating
- KeyBanc upgrades Exagen on improved revenue visibility
- Exagen Inc. Reports Record Q2 2025 Revenue
- Exagen’s Promising Financial Trajectory and Raised Price Target Amid Strong Performance and Strategic Growth Initiatives